Why Wealthy Investors Are Quietly Betting Big on AI and HealthTech

Jan de Vries · 2026-10-12

Investment ambitions across the EU for AI and HealthTech are expansive. The EU's InvestAI initiative aims to mobilise €200 billion for artificial intelligence, including funding for major AI infrastructure. That's not a typo — €200 billion (roughly $216 billion) aimed squarely at the technology reshaping everything from drug discovery to manufacturing. The European Commission and the European Investment Bank Group have also launched BioTechEU to mobilise €10 billion (about $10.8 billion) for biotech and life sciences in 2026 and 2027. That investment push comes as AI and healthcare are becoming increasingly popular among wealthy private investors globally. The UBS Global Family Office Report 2026, for example, found that 65% of family offices were already invested in AI, and 33% were allocated to AI-enabled healthcare. So why is so much private capital moving toward AI and HealthTech? Let's break it down. ### Investing in AI and HealthTech in 2026 The scale of the EU's investment and infrastructure plans shows how strategically important AI has become. Infrastructure is one of the clearest examples. In July 2026, the EU requested up to seven AI Gigafactories, backed by up to €10 billion in EU and national funding, and expected to unlock at least €20 billion in additional private investment across the Union. Life sciences are also an important part of the EU economy, already contributing nearly €1.5 trillion (around $1.6 trillion) in value and supporting 29 million jobs. The EU is now trying to increase investment further through initiatives such as BioTechEU, designed to mobilise €10 billion for biotechnology and life sciences investment during 2026 and 2027. The European Commission's wider life sciences strategy also includes measures to make it easier to fund multi-country clinical trials, plus €300 million (about $324 million) to stimulate the procurement of life sciences innovations, including next-generation vaccines and affordable cancer solutions. As investment moves into high-growth sectors, investors can also explore private-market opportunities through firms operating across venture capital, private equity, and real estate markets. ### AI and HealthTech Sector Growth The EU has a massive life sciences industry with major research institutions, healthcare systems, and rapidly expanding AI infrastructure, which helps explain investor interest. By April 2026, 19 AI Factories had been deployed across European supercomputers, supported by 13 regional AI Factory antennas, giving researchers, startups, and businesses greater access to AI computing capacity. EU and participating EuroHPC countries have committed more than €2.6 billion to the AI Factories and Antennas initiative. Then you've got the healthcare side. The European Health Data Space is designed to make health data easier to access and reuse securely across the EU for research, innovation, and regulatory purposes. That creates potentially valuable infrastructure for areas such as medical research and AI development. Other EU projects include building specialist datasets, including Cancer Image Europe, which is expected to provide access to 60 million cancer images by the end of 2026, and the 1+ Million Genomes initiative, which aims to provide secure access to genomic and associated clinical data. Interestingly, the EU is also trying to move AI from research into clinical settings. In 2026, the European Commission made €9 million (roughly $9.7 million) available for two large-scale pilots of AI-powered medical imaging, covering technologies such as X-rays, CT scans, MRI, PET, and ultrasound. For investors, the attraction is that HealthTech is moving beyond laboratory research into real-world clinical testing and EU-backed deployment programmes. ### Massive Capital Rotation From High-Net-Worth Investors It's difficult to track exactly what every high-net-worth individual is investing in. Much private investment isn't publicly disclosed. But the family office data tells a pretty clear story. > "We're seeing a genuine rotation," one family office advisor noted. "The money isn't chasing hype anymore — it's chasing infrastructure, data, and clinical outcomes." Here's what's driving the shift: - **Government backing reduces risk.** When the EU commits billions to AI factories and biotech, private investors see a safety net. - **Data is the new moat.** Health data spaces and genomic initiatives create assets that are hard to replicate. - **Clinical validation is arriving.** AI medical imaging pilots move the technology from lab to bedside. - **Diversification matters.** AI and HealthTech offer growth uncorrelated with traditional markets. The takeaway? The EU isn't just talking about AI and HealthTech. It's building the infrastructure, funding the research, and clearing the regulatory path. For high-net-worth investors, that combination is hard to ignore.